Marker Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Marker Therapeutics Inc MRKR.OQ reported a quarterly adjusted loss of 29 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -25 cents. The mean expectation of two analysts for the quarter was for a loss of 41 cents per share. Wall Street expected results to range from -55 cents to -27 cents per share.

• Revenue fell 26.3% to $861.00 thousand from a year ago; analysts expected $723.00 thousand.

• Marker Therapeutics Inc's reported EPS for the quarter was a loss of 29 cents​.

• The company reported a quarterly loss of $4.02 million.

• Marker Therapeutics Inc shares had fallen by 15.7% this quarter and lost 58.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 25.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Marker Therapeutics Inc is $8.00, about 84.4% above its last closing price of $1.25

This summary was machine generated from LSEG data August 15 at 01:09 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)